Connection

James Ballenger to Middle Aged

Back to Details
This is a "connection" page, showing publications James Ballenger has written about Middle Aged.
James Ballenger
Connection Strength
0.342
Middle Aged
  1. A pilot study of vagus nerve stimulation (VNS) for treatment-resistant anxiety disorders. Brain Stimul. 2008 Apr; 1(2):112-21.
    View in: PubMed
    Score: 0.021
  2. Remission rates in patients with anxiety disorders treated with paroxetine. J Clin Psychiatry. 2004 Dec; 65(12):1696-707.
    View in: PubMed
    Score: 0.017
  3. A controlled trial of daily left prefrontal cortex TMS for treating depression. Biol Psychiatry. 2000 Nov 15; 48(10):962-70.
    View in: PubMed
    Score: 0.013
  4. Multiple previous alcohol detoxifications are associated with decreased medial temporal and paralimbic function in the postwithdrawal period. Alcohol Clin Exp Res. 1999 Jun; 23(6):1077-84.
    View in: PubMed
    Score: 0.012
  5. Sleep Deprivation in social phobia and generalized anxiety disorder. Biol Psychiatry. 1998 Jun 01; 43(11):840-2.
    View in: PubMed
    Score: 0.011
  6. Comorbidity of panic and depression: implications for clinical management. Int Clin Psychopharmacol. 1998 Apr; 13 Suppl 4:S13-7.
    View in: PubMed
    Score: 0.011
  7. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry. 1998 Jan; 155(1):36-42.
    View in: PubMed
    Score: 0.010
  8. Discussion and overview: what can we learn if we view panic disorder across the life span and across different presentations and contexts? Bull Menninger Clin. 1997; 61(2 Suppl A):A95-102.
    View in: PubMed
    Score: 0.010
  9. Clinical evaluation of venlafaxine. J Clin Psychopharmacol. 1996 Jun; 16(3 Suppl 2):29S-35S; discussion 35S-36S.
    View in: PubMed
    Score: 0.009
  10. The DSM-IV panic disorder field trial: panic attack frequency and functional disability. Anxiety. 1996; 2(4):157-66.
    View in: PubMed
    Score: 0.009
  11. Body dysmorphic disorder in patients with anxiety disorders and major depression: a comorbidity study. Am J Psychiatry. 1995 Nov; 152(11):1665-7.
    View in: PubMed
    Score: 0.009
  12. Plasma pyridoxal phosphate in anxiety disorders. Biol Psychiatry. 1994 Nov 01; 36(9):606-8.
    View in: PubMed
    Score: 0.008
  13. Somatic symptoms in generalized anxiety disorder with and without comorbid psychiatric disorders. Am J Psychiatry. 1994 Jun; 151(6):930-2.
    View in: PubMed
    Score: 0.008
  14. Psychiatric comorbidity in patients with generalized anxiety disorder. Am J Psychiatry. 1993 Aug; 150(8):1216-8.
    View in: PubMed
    Score: 0.008
  15. Comment on the London/Toronto Study of Alprazolam and Exposure in Panic Disorder with Agoraphobia. Br J Psychiatry. 1993 Jun; 162:788-9; discussion 790-4.
    View in: PubMed
    Score: 0.008
  16. Cardiovascular effects of imipramine, fluvoxamine, and placebo in depressed outpatients. J Clin Psychiatry. 1993 Jun; 54(6):224-8.
    View in: PubMed
    Score: 0.008
  17. Prevalence of psychiatric disorders in patients with irritable bowel syndrome. Psychosomatics. 1993 May-Jun; 34(3):229-34.
    View in: PubMed
    Score: 0.008
  18. Effect of fluvoxamine, imipramine and placebo on catecholamine function in depressed outpatients. J Psychiatr Res. 1993 Apr-Jun; 27(2):161-72.
    View in: PubMed
    Score: 0.008
  19. Preliminary report: placebo-controlled, double-blind study of the clinical and metabolic effects of desipramine in panic disorder. Psychopharmacol Bull. 1993; 29(2):183-8.
    View in: PubMed
    Score: 0.007
  20. Cardiovascular status of panic disorder patients with and without prominent cardiac symptoms. Psychosomatics. 1992; 33(1):81-4.
    View in: PubMed
    Score: 0.007
  21. Effect of alprazolam on depression in panic disorder. J Clin Psychopharmacol. 1991 Apr; 11(2):145-6.
    View in: PubMed
    Score: 0.007
  22. The first double-blind, placebo-controlled trial of a partial benzodiazepine agonist abecarnil (ZK 112-119) in generalized anxiety disorder. Psychopharmacol Bull. 1991; 27(2):171-9.
    View in: PubMed
    Score: 0.006
  23. Pergolide mesylate treatment of cocaine withdrawal. J Clin Psychiatry. 1991 Jan; 52(1):39-40.
    View in: PubMed
    Score: 0.006
  24. Brain MRI in obsessive-compulsive disorder. Psychiatry Res. 1991 Jan; 36(1):45-9.
    View in: PubMed
    Score: 0.006
  25. Panic and phobic disorders in patients with obsessive compulsive disorder. J Clin Psychiatry. 1990 Nov; 51(11):456-8.
    View in: PubMed
    Score: 0.006
  26. Rapid response of patients simultaneously treated with lithium and nortriptyline. J Clin Psychiatry. 1990 Mar; 51(3):124-5.
    View in: PubMed
    Score: 0.006
  27. Phenelzine treatment of panic disorder: lack of effect on pyridoxal phosphate levels. J Clin Psychopharmacol. 1989 Dec; 9(6):428-31.
    View in: PubMed
    Score: 0.006
  28. Fluvoxamine, imipramine, and placebo in the treatment of depressed outpatients: effects on depression. Psychopharmacol Bull. 1989; 25(1):68-70.
    View in: PubMed
    Score: 0.006
  29. Electroencephalography during sleep of patients with panic disorder. J Neuropsychiatry Clin Neurosci. 1989; 1(4):372-6.
    View in: PubMed
    Score: 0.006
  30. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment. Arch Gen Psychiatry. 1988 May; 45(5):413-22.
    View in: PubMed
    Score: 0.005
  31. Alcohol detoxification and withdrawal seizures: clinical support for a kindling hypothesis. Biol Psychiatry. 1988 Mar 01; 23(5):507-14.
    View in: PubMed
    Score: 0.005
  32. Alprazolam in the treatment of social phobia. J Clin Psychiatry. 1988 Jan; 49(1):17-9.
    View in: PubMed
    Score: 0.005
  33. Psychopharmacology of the anxiety disorders. Psychiatr Clin North Am. 1984 Dec; 7(4):757-71.
    View in: PubMed
    Score: 0.004
  34. Tricyclic antidepressant use in a patient with bundle branch blocks and ventricular ectopy. J Clin Psychiatry. 1984 Aug; 45(8):353-5.
    View in: PubMed
    Score: 0.004
  35. Carbamazepine in alcohol withdrawal syndromes and schizophrenic psychoses. Psychopharmacol Bull. 1984; 20(3):572-84.
    View in: PubMed
    Score: 0.004
  36. Carbamazepine in manic-depressive illness: a new treatment. Am J Psychiatry. 1980 Jul; 137(7):782-90.
    View in: PubMed
    Score: 0.003
  37. The economic burden of anxiety disorders in the 1990s. J Clin Psychiatry. 1999 Jul; 60(7):427-35.
    View in: PubMed
    Score: 0.003
  38. Once-weekly dosing of fluoxetine in the maintenance of remission in panic disorder. J Clin Psychiatry. 1999 May; 60(5):299-301.
    View in: PubMed
    Score: 0.003
  39. Alcohol and central serotonin metabolism in man. Arch Gen Psychiatry. 1979 Feb; 36(2):224-7.
    View in: PubMed
    Score: 0.003
  40. Feasibility of using fMRI to study mothers responding to infant cries. Depress Anxiety. 1999; 10(3):99-104.
    View in: PubMed
    Score: 0.003
  41. A double-blind evaluation of the safety and efficacy of abecarnil, alprazolam, and placebo in outpatients with generalized anxiety disorder. Abecarnil Work Group. J Clin Psychiatry. 1997; 58 Suppl 11:11-8.
    View in: PubMed
    Score: 0.002
  42. Comorbidity of posttraumatic stress disorder and irritable bowel syndrome. J Clin Psychiatry. 1996 Dec; 57(12):576-8.
    View in: PubMed
    Score: 0.002
  43. Long-term follow-up after a drug trial for panic disorder. Br J Psychiatry. 1995 Oct; 167(4):487-94.
    View in: PubMed
    Score: 0.002
  44. A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder. Biol Psychiatry. 1995 Apr 01; 37(7):462-6.
    View in: PubMed
    Score: 0.002
  45. Infrequent panic attacks: psychiatric comorbidity, personality characteristics and functional disability. J Psychiatr Res. 1995 Mar-Apr; 29(2):121-31.
    View in: PubMed
    Score: 0.002
  46. Predictors of response to alprazolam and placebo in patients with panic disorder. J Affect Disord. 1994 Jan; 30(1):5-13.
    View in: PubMed
    Score: 0.002
  47. Electroconvulsive therapy and cardiac pacemakers. Psychosomatics. 1973 Jul-Aug; 14(4):233-4.
    View in: PubMed
    Score: 0.002
  48. CSF cholecystokinin concentrations in patients with panic disorder and in normal comparison subjects. Am J Psychiatry. 1992 May; 149(5):691-3.
    View in: PubMed
    Score: 0.002
  49. A fixed-dose study of alprazolam 2 mg, alprazolam 6 mg, and placebo in panic disorder. J Clin Psychopharmacol. 1992 Apr; 12(2):96-103.
    View in: PubMed
    Score: 0.002
  50. Dopamine blocking activity of clomipramine in patients with obsessive-compulsive disorder. Biol Psychiatry. 1991 Aug 01; 30(3):225-32.
    View in: PubMed
    Score: 0.002
  51. Secondary depression in panic disorder and agoraphobia. II. Dimensions of depressive symptomatology and their response to treatment. J Affect Disord. 1989 Jan-Feb; 16(1):49-58.
    View in: PubMed
    Score: 0.001
  52. Different rates of improvement of different symptoms in combined pharmacological and behavioral treatment of agoraphobia. J Behav Ther Exp Psychiatry. 1988 Jun; 19(2):119-26.
    View in: PubMed
    Score: 0.001
  53. The effects of lithium on neuroendocrine function in affectively ill patients. Acta Psychiatr Scand. 1986 May; 73(5):524-8.
    View in: PubMed
    Score: 0.001
  54. Neuroendocrine effects of carbamazepine in patients with affective illness. Epilepsia. 1986 Mar-Apr; 27(2):156-60.
    View in: PubMed
    Score: 0.001
  55. Neuroendocrine effects of the dopamine agonist piribedil in depressed patients. Clin Neuropharmacol. 1986; 9(5):448-55.
    View in: PubMed
    Score: 0.001
  56. The dexamethasone suppression test in agoraphobia. J Clin Psychopharmacol. 1985 Apr; 5(2):100-2.
    View in: PubMed
    Score: 0.001
  57. Prophylactic efficacy of carbamazepine in manic-depressive illness. Am J Psychiatry. 1983 Dec; 140(12):1602-4.
    View in: PubMed
    Score: 0.001
  58. Tetrahydrobiopterin levels in cerebrospinal fluid of affectively ill patients. Lancet. 1983 Jul 02; 2(8340):55-6.
    View in: PubMed
    Score: 0.001
  59. CSF dopamine beta-hydroxylase in schizophrenia. Arch Gen Psychiatry. 1983 Jul; 40(7):743-7.
    View in: PubMed
    Score: 0.001
  60. Carbamazepine and its -10,11-epoxide metabolite in plasma and CSF. Relationship to antidepressant response. Arch Gen Psychiatry. 1983 Jun; 40(6):673-6.
    View in: PubMed
    Score: 0.001
  61. The effect of lithium on the osmoregulation of arginine vasopressin secretion. J Clin Endocrinol Metab. 1983 Feb; 56(2):295-9.
    View in: PubMed
    Score: 0.001
  62. Neurohypophyseal function in affective illness. Psychopharmacol Bull. 1983; 19(3):426-31.
    View in: PubMed
    Score: 0.001
  63. Effect of carbamazepine on cyclic nucleotides in CSF of patients with affective illness. Biol Psychiatry. 1982 Sep; 17(9):1037-45.
    View in: PubMed
    Score: 0.001
  64. Central nervous system gamma-aminobutyric acid activity in man. Relationship to age and sex as reflected in CSF. Arch Neurol. 1982 Apr; 39(4):247-9.
    View in: PubMed
    Score: 0.001
  65. Depressed patients have decreased binding of tritiated imipramine to platelet serotonin "transporter". Arch Gen Psychiatry. 1981 Dec; 38(12):1315-7.
    View in: PubMed
    Score: 0.001
  66. The effect of pimozide on CSF norepinephrine in schizophrenia. Am J Psychiatry. 1981 Aug; 138(8):1045-50.
    View in: PubMed
    Score: 0.001
  67. Effects of vasopressin on human memory functions. Science. 1981 Feb 06; 211(4482):601-3.
    View in: PubMed
    Score: 0.001
  68. Plasma and CSF MHPG in normals [proceedings]. Psychopharmacol Bull. 1981 Jan; 17(1):86-7.
    View in: PubMed
    Score: 0.001
  69. Lack of effect of carbamazepine on gamma-aminobutyric acid in cerebrospinal fluid. Neurology. 1980 Sep; 30(9):1008-11.
    View in: PubMed
    Score: 0.001
  70. Immunoreactive calcitonin in cerebrospinal fluid of man. Brain Res. 1980 Aug 04; 194(2):598-602.
    View in: PubMed
    Score: 0.001
  71. Dopamine beta-hydroxylase in CSF. Relationship to personality measures. Arch Gen Psychiatry. 1980 Mar; 37(3):308-10.
    View in: PubMed
    Score: 0.001
  72. Dopamine-beta-hydroxylase in the cerebrospinal fluid: relationship to disulfiram-induced psychosis. Biol Psychiatry. 1979 Apr; 14(2):337-44.
    View in: PubMed
    Score: 0.001
  73. Dopamine-beta-hydroxylase in the cerebrospinal fluid of psychiatric patients. Biol Psychiatry. 1978 Dec; 13(6):685-94.
    View in: PubMed
    Score: 0.001
  74. Cerebrospinal fluid homovanillic acid in male alcoholics: effects of disulfiram. Biol Psychiatry. 1977 Oct; 12(5):635-42.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.